SRTS Earnings Prediction
The chart below shows how SRTS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SRTS sees a -2.65% change in stock price 10 days leading up to the earnings, and a -0.84% change 10 days following the report. On the earnings day itself, the stock moves by +0.89%. This data can give you a slight idea of what to expect for the next quarter's release.
SRTS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
13.07M
3.98%
47.83%
Gross Margin
54.39%
-12.71%
-8.25%
Operating Margin
13.21%
-70.23%
-21.88%
Net Margin
11.83%
-64.69%
-13.96%
EPS
0.09
-65.38%
28.57%
No Data Available
SRTS Earnings Analysis
Sensus Healthcare Inc Corporation (SRTS.O) Earnings Conference Call
Positive
Q4 Revenue Surge: Revenue for Q4 2024 reached $13.1 million, a 71% increase compared to $7.7 million in Q4 2023, driven by higher unit sales of SRT-100 systems.
SRT-100 System Shipments Growth: A record of 39 SRT-100 systems were shipped in Q4 2024, marking an 18% increase from the previous quarter, and a total of 115 systems shipped for the full year, a 74% increase year-over-year.
Quarterly Profitability Achievement: Net income for Q4 2024 was $1.4 million, achieving the fifth consecutive quarter of profitability, with a full-year net income of $6.6 million, compared to $0.5 million in 2023.
Strong Capital Position: The company ended 2024 with $22.1 million in cash and cash equivalents and no debt, reflecting a strong capital position to support ongoing R&D and growth initiatives.
EBITDA Improvement Analysis: Adjusted EBITDA for 2024 was $8.7 million, a significant improvement from $0.3 million in 2023, indicating strong operational performance and profitability.
Negative
Gross Profit Decline: Gross profit decreased to 7.1 million or 54.4% of revenues, down from 7.8 million or 62.3% of revenues in the prior year quarter, primarily due to a one-time discount to a new large group customer and higher service costs.
Rising Operational Costs: General and administrative expenses increased to 2.4 million compared with 0.9 million last year, mainly due to higher compensation and professional fees, indicating rising operational costs.
Net Income Decline: Net income for Q4 2024 was 1.5 million or $0.09 per diluted share, compared with 4.2 million or $0.26 per diluted share a year ago, reflecting a significant decline in profitability.
EBITDA Decline Analysis: Adjusted EBITDA was 1.9 million compared with 5.7 million in the fourth quarter of 2023, highlighting a substantial drop in operational efficiency and profitability.
Sales Decline Forecast: Sales for the first quarter of 2025 are expected to be considerably lower than the first quarter of 2024, indicating potential challenges in maintaining revenue momentum.
SRTS FAQs
How does SRTS typically perform around its earnings report dates?
Is Sensus Healthcare Inc (SRTS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SRTS Earning Call Sentiment
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2024 Earnings Call Transcript
SRTS.O
0%Positive
The earnings call presents a mixed picture: strong revenue growth and strategic expansions are positive, but declining margins and operational risks are concerning. The absence of share buyback or dividend programs is neutral, while supply chain challenges and economic factors could dampen growth. The Q&A session highlights management's lack of specificity in addressing future metrics and customer inclination towards the fair deal agreement. Without clear guidance or a significant partnership announcement, the stock price is likely to remain stable in the short term.
